All In Biotech

Investigational drug · Phase 2

MORF-057

Also called: zotemtegrast, LY4268989

Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Inflammatory Bowel Diseases, Crohn's Disease, Ulcerative Colitis (UC).

Phase 2

Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

4

3 still active

All registered trials

8

Any phase or sponsor naming "MORF-057"

First trial start

2022

Nov 21, 2022

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "MORF-057", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Inflammatory Bowel Diseases
  • Crohn's Disease
  • Ulcerative Colitis (UC)
  • Ulcerative Colitis, Active Moderate
  • Ulcerative Colitis, Active Severe
  • Ulcerative Colitis
  • Colitis, Ulcerative

Approved drugs for the same conditions: Crohn's disease · Ulcerative colitis · Immunology and inflammation · Gastroenterology and liver

Largest trials

Live from ClinicalTrials.gov: studies naming "MORF-057" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 2 on PubMed

Also in development for Inflammatory Bowel Diseases

  • SPY001SPY001-001Phase 22 trials

    Spyre Therapeutics, Inc. · Ulcerative Colitis, Inflammatory Bowel Diseases, Colitis

  • SPY002SPY002-091Phase 22 trials

    Spyre Therapeutics, Inc. · Ulcerative Colitis, Inflammatory Bowel Diseases, Colitis

  • SPY003SPY003-207Phase 22 trials

    Spyre Therapeutics, Inc. · Ulcerative Colitis, Inflammatory Bowel Diseases, Colitis

  • ATH-063Phase 21 trial

    Athos Therapeutics Inc · Ulcerative Colitis, Inflammatory Bowel Diseases, Autoimmune Diseases

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.